Author Index to Volume 6 (1989)

Aarons, L., 367, 660
Abbiati, G., 571
Adams, W., 731
Ageel, A., 252
Agrawala, P., 355
Ahmed, I., 772
Al-Obeid, H., 252
Al-Rashood, K., 252
Alexander, J., 501
Alhaider, A., 394
Alvarez, F., 449, 555
Amer, M., 492
Amidon, G., 66, 1043
Anderson, B., 210
Anderson, W., 592
Aramaki, Y., 362
Asker, A., 58
Aspacher, G., 332
Asthana, O. P., 1048
Au, J., 318, 323
Audus, K., 160, 624
Aungst, B., 244

Bagdon, R., 1000
Baker, P., 387
Baldoni, J., 892
Balis, E., 863
Ball, L., 13
Barone, D., 571
Baveja, S., 313
Beall, R., 525
Behl, C., 85, 740
Benet, L., 125, 486
Benita, S., 510
Bergstrom, R., 20
Betageri, G., 399
Bialer, M., 683
Bierman, R., 1000
Bilicki, C., 794
Bockbrader, H., 924
Boddy, A., 203, 376
Bodmeier, R., 413, 725
Bodor, N., 592, 667
Boer, A., 91
Boppana, V., 702
Borchardt, R., 466, 624, 903
Borin, M., 619, 794
Boucher, R., 525
Bowers, L., 601
Brake, N. W., 1032
Bramer, S., 318
Braun, R., 13
Brazeau, G., 167, 766
Bredberg, U., 817
Brossel, S., 660
Brucks, R., 697
Byars, N., 748
Bynum, L., 62
Byron, P., 225

Cabana, B., 13
Callery, P., 706
Canafax, D., 279, 601
Capobianco, M., 216
Caputo, J., 731, 809
Cardozo, L., 182, 528
Cargill, R., 506
Cates, L., 737
Catz, P., 938
Ceserani, R., 571
Chan, K., 719
Chan, T., 28
Chang, T., 924
Chapman, J., 709
Chapman, M., 230
Chareonboonsit, P., 714
Che, C., 637
Chen, H., 413
Chen, J., 408
Cheng, H., 4, 133, 258
Chiao, C., 517
Chien, T-y., 1000
Chien, Y., 753, 848
Chien, Y. W., 1000
Chiou, W., 833, 840, 1056
Cho, M., 71, 78
Choi, L., 328
Chow, D., 408
Chow, M., 428
Chungi, V., 1067
Ciliax, B., 474
Cintrón, S., 481
Cipolle, R., 601
Citterio, F., 255
CoffinBeach, D., 844
Colofiore, J., 863
Cook, K., 809
Corbo, D., 848
Corbo, M., 753
Cortese, M., 501
Counsell, D., 1011
Cramer, C., 71
Crommelin, D., 787
Cyronak, M., 702

Dalby, R., 225
Dandekar, K., 895
Danhof, M., 585
Daniel, L., 216
Das, S., 945
Davis, P., 982
Davis, S., 274
Dawson, R., 592
De Graft-Johnson, D., 20
Debono, M., 387
DeForge, L., 1011
DeGalan, M., 1011
Del Terzo, S., 85
DeLuca, P., 961
Dent, J., 44
Desai, A., 719
Desbonnet, C., 119
deSilva, J., 328
Deurloo, M., 853
Devi, K., 313
DiLuccio, R., 49, 844, 1052
DiLuccio, R., 1052
Dingemanse, J., 585
Dittert, L., 1067
Dixon, R., 28
Doelker, E., 578
Dong, X., 637
Dowty, M., 100
Duncan-Hewitt, W., 373, 1060

Eatough, D., 20
Edwards, P., 203
Eickhoff, W., 44
El—Yazigi, A., 492
Eling, W., 787
Elsberry, D., 601
Engle, K., 501, 506
Erdmann, G., 279
Everett, R., 612

Fagan, S., 248
Farid, K., 387
Farnsworth, N., 637
Fathi, M., 313
Feely, L., 274
Finnegan, P., 804
Fix, J., 501, 506
Fleeker, C., 443
Fleishaker, J., 379
Fleisher, D., 332
Fleitman, J., 748
Flynn, G., 147, 825
Fong, H., 637
Foster, L., 748
Fox, K., 706
Francoeur, M., 772
Fraser, R., 677
Friedman, D., 1043
Friend, D., 938
Friis, J., 53
Fu, R., 748
Fujihara, Y., 1025
Fukanoki, S., 338
Fung, H.-L., 167, 766

Gabrielsson, J., 677
Gander, B., 578
Gardner, C., 506
Garren, K., 966
Gengo, F., 248
Gerdin, B., 677
Giebink, S., 279
Gildersleeve, D., 474
Glikfeld, P., 988
Gobbi, M., 571
Gottschalk-Sabag, S., 510
Gould, F., 601
Grass, G., 759, 852
Green, P., 628
Grevel, J., 255
Griffin, H., 332
Grover, P., 988, 1048
Gruber, S., 601
Gu, L., 968
Guillory, K., 608
Gunnarsson, L., 318, 323
Gupta, B., 945

0724-8741/89/1200-1077$06.00/0 © 1989 Plenum Publishing Corporation

Gupta, R., 991, 1048
Gurny, R., 578
Guy, R., 949, 988
Guzek, D., 33

Habib, M., 58
Hadgraft, J., 628
Hahn, L., 958
Haigh, J., 431
Haj-Yehia, A., 683
Hall, I., 230
Hall, L., 497
Hanano, M., 192, 235
Hansen, L., 20
Harboe, E., 919, 995
Hartauer, K., 608
Hashida, M., 140, 931
Hashimoto, M., 171
Hegde, S., 737
Heijligers-Feijen, C., 91
Heller, P., 938
Helman, M., 883
Hem, S., 619, 794
Hermens, W., 853
Hickey, A., 225
Higuchi, W., 798
Hijazi, A., 394
Hinz, R., 988
Hirano, K., 302, 308
Hoffman, A., 976
Hollander-Jansen, M., 585
Honc, F., 328
Hoogdalem, E., 91
Hopkins, K., 660
Hopkins, N., 248
Hori, R., 813, 877, 954
Hrushesky, W., 601
Hsiao, J., 28
Hu, M., 66
Huang, Y., 1000
Huntington, J., 286
Hurwitz, A., 844, 1052
Hussain, M., 49, 186, 844, 1052
Hynes, P., 601
Hyon, S., 338

Ichikawa, M., 342
Ichimura, F., 486
Iga, T., 235
Ignarro, L., 651
Iguchi, S., 1025
Ikada, Y., 296, 338, 422
Imai, T., 156
Imamura, Y., 156
Inaba, M., 690
Inui, K., 954
Ishac, K., 216
Ishii, Y., 342
Iwakawa, S., 125, 813

James, J., 892
Jenke, D., 96
Johansen, M., 919, 995
John, V., 328, 719
Johnson, D., 867
Johnson, K., 239
Jonkman, J., 13
Juhn, S., 279
Jung, D., 62, 697
Jusko, W., 4, 133, 262

Kahan, B., 255
Kakutani, T., 140
Kamat, M., 961
Kamiya, A., 877
Kaneo, Y., 1025
Karali, T., 804
Karlsson, M., 817
Kato, M., 954
Kaul, S., 895
Kellaway, I., 633
Kennedy, A., 33
Kier, L., 497
Kimachi, K., 156
Kimpton, W., 677
Kirsch, L., 387
Kiso, Y., 171
Klech, C., 564
Klockowski, P., 404
Klotz, U., 1
Knowlton, P., 477
Knutson, K., 798
Ko, H., 731
Kochak, G., 328
Komada, F., 813
Konechnik, T., 619
Konecny, J., 612
Kos, R., 619
Kosh, J., 709
Koshida, R., 486
Kozawa, Y., 1025
Kramer, W., 481
Krill, S., 798
Kriwacki, R., 531
Kumar, S., 740

Lakings, D., 53
Lambert, W., 798
Langemeijer, M., 585
Langerman, L., 510
Larsen, C., 919, 995
Laurent, T., 677
Le, C., 279
Lebel, L., 677
Ledoux, K., 892
Lee, H.-J., 833, 840
Leeson, L., 13
Leest, K., 787
LeMarchand, A., 1039
Leppert, P., 501
Levy, G., 404, 976
Levy, M., 510
Lewis, E., 20
Li, V.-S., 737
Lidgate, D., 748
Lin, E., 125
Lin, L.-H., 971
Ling, T., 62
Liu, J.-C., 753, 848
Liversidge, G., 44
Lodder, R., 961
Longer, M., 100
Lukacsko, B., 883
Lunan, C., 53

Madani, A., 252
Madden, P., 714
Maegawa, H., 954
Malick, W., 740
Maloney, P., 867
Manning, M., 903
Martin, C., 492
Martin, D., 863
Maruyama, T., 156
Matas, A., 601
Matsuyama, K., 342
McConnel, D., 1011
McCullough, B., 612
McFadden, M., 332
McGreevy, K., 867
McGuiggan, M., 601
McNally, W., 924
McNeill, S., 33, 119
Meijer, D., 105
Menneni, T., 571
Merkus, F., 853
Mitra,A., 887
Modest, E., 216
Mohrland, J., 53
Mojaverian, P., 719
Molloy, M., 387
Mondranondra, I., 637
Morehead, W., 759
Morgan, D., 874
Mori, H., 1025
Morimoto, K., 338
Morisaka, K., 338
Morton, J., 28
Mosberg, H., 66
Mroszcek, E., 62
Muranishi, N., 302, 308
Muranishi, S., 171
Mustafa, A., 394
Mutschler, E., 152

Nagayasu, A., 338
Nakamura, J., 342
Nakano, M., 342
Nakashima, E., 486
Nakashima, M., 342
Nanavaty, M., 697
Narurkar, M., 887
Nash, R., 85
Needham, T., 804
Neubert, R., 743
Nishida, K., 140
Nishihata, T., 286
NityaNand, S., 1048
Nonomura, N., 279
Noorizadeh, C., 612
Noseda, A., 216

Oguma, T., 302, 308
Okagaki, M., 938
Okamoto, H., 931
Okudaira, K., 235
Okumura, K., 813, 877
Olesen, H., 919, 995
Otagiri, M., 156

Paeratakul, O., 413, 725
Pal, M., 945
Paliwal, J., 991, 1048
Palm, D., 152
Pandit, N., 177
Pari, J., 564
Pastel, M., 892
Patel, K., 903
Patel, S., 740
Patton, T., 772
Peeters, P., 787
Peppas, N., 578
Petrak, K., 367
Petre, W., 210
Pflugmann, G., 152
Phelan, M., 667
Phillips, P., 379
Piantadosi, C., 216
Pidgeon, C., 779
Pirat, J. L., 474
Pitha, J., 641
Pitner, P., 531

Pittman, K., 895
Plebani, M., 255
Porter, P., 506
Potts, R., 33, 119
Pramanik, B., 28
Prasa, V., 13
Price, J., 418, 517
Pulham, D., 734
Purdie, N., 521
Purich, E., 13
Putcha, L., 481

Rahman, Y., 601
Rao, K., 313
Re, T., 883
Repta, A., 501, 966
Restelli, G., 571
Ridout, G., 628
Rigotti, P., 255
Ritz, J., 601
Robinson, J., 100
Rogers, J., 399
Romeyn, S., 853
Roskos, K., 949
Rosler, K. H., 706
Roth, M., 313, 924
Rowe, S., 186
Rowland, M., 203, 660
Roy, S., 147, 825, 945
Rutledge, D., 182, 528
Rytting, H., 286, 443

Sager, A., 1039
Saito, K., 931
Sasaki, H., 342
Sawyer, R., 863
Schroeder, S., 779
Schuster, D., 248
Schwender, S., 1011
Scieska, J., 71, 78
Seino, Y., 813
Semmes, R., 734
Seul, C., 804
Sevelius, H., 62
Sezaki, H., 140
Shah, D., 239
Shah, J., 408
Shah, M., 624
Shah, V., 346, 612
Shargel, L., 1067
Shefter, E., 49, 844, 1052
Shenvi, A., 186
Sheth, N., 332
Shibasaki, J., 342
Shiu, G., 1039
Shukla, A., 418
Siegel, F., 697
Simpkins, J., 592
Sisco, J., 177
Skelly, J., 346, 612, 1039
Sluijs, P., 105
Smith, E., 431
Smith, K., 466
Smith, R., 328, 379
Smith, T., 379
Smulkowski, M., 28
Soine, P., 458
Soine, W., 458
Sowell, W., 709
Spahn, H., 125, 152
Sparer, R., 506
Srivastava, J., 1048
Steinberg, J., 182, 528
Stella, V., 449, 555
Stevens, J., 633
Stote, R., 702
Streng, W. H., 1032
Strickly, R., 971
Subramanian, P., 66
Sucker, H., 961
Suenaga, A., 156
Sugiyama, Y., 192, 235, 690
Suryanarayanan, R., 1017
Svensson, C., 477
Swallows, K., 521
Sweetana, S., 857

Tabata, Y., 296, 422
Tahir, K., 252
Takada, K., 171
Takano, M., 954
Tanaka, T., 1025
Taniguchi, N., 486
Tarr, B., 40
Tavakoli, M., 160
Taylor, G., 633, 641
Taylor, K., 633
Teagarden., 210
Testa, R., 571
Thiercelin, J. F., 660
Thombre, A., 772
Thompson, D., 71, 78
Tipnis, V., 328
Tonegawa, C., 140
Topp, E., 966
Torosian, G., 844
Tsuchiya, S., 362
Tsui, J., 481
Tsuji, A., 486
Tucker, I., 100
Tyle, P., 355
Tymes, N., 346

Uetrecht, J., 265
Unadkat, J., 734
Unseld, E., 1

Van Dort, M., 474
Vanasia, A., 571
VanderLugt, J., 53
VanderPloeg, J., 481
Veillard, M., 100
Velagapud, R., 1039
Venkataram, S., 601
Venuti, M., 867
Verhoef, C., 91, 853
Vest, F., 458
Vetticaden, S. J., 13
Vidmar, T., 71, 78
Visor, G., 971

Wagner, D., 248
Wakshull, E., 33, 119
Walker, J., 404
Wang, J. P., 734
Watanabe, T., 690
Waters, R., 706
Weatherly, G., 373, 1060
Weidler, D., 328
Weiss, J., 641
Wellstein, A., 152
Westermann-Clark, G., 239
Westkaemper, R., 458
White, J., 619, 794
Wieland, D., 474
Wierzba, K., 235
Williard, R., 779
Wong, O., 230, 286, 443
Wong, Y. W., 982
Wright, J., 706
Wu, A., 62

Yalkowsky, S., 40
Yamada, H., 302, 308
Yamamichi, R., 156
Yamashita, F., 931
Yang, D., 474
Yoshida, H., 877
Yoshida, M., 302, 308
Yoshikawa, T., 302, 308
Young, A., 474
Young, J., 867
Young, R., 924

Zeeuw, R., 13
Zhao, H., 428
Ziemniak, J., 702

Subject Index to Volume 6 (1989)

(thr 1)-muramyldipeptide, 748
β-adrenoceptor antagonist, metoprolol, 152
α-aminoboronic acid derivatives, aminopeptidase inhibitors, 186
β-elimination, protein degradation, 903
α_1-acid glycoprotein binding of acidic and basic drugs, 156
α_1-acid-glycoprotein (orosomucoid), 107
2′,3′-didehydro-3′-deoxythymidine plasma levels, rat, monkey, 895
2′,3′-didehydro-3′-deoxythymidine, HPLC, 895
3-hydroxymethyl phenytoin, 555
3-hydroxymorphinan, 13
3-methoxymorphinan, 13
5-bromoindole, NMR, 531
5-fluorouracil prodrug, 5′-deoxy-5-fluorouridine, 323
5-fluorouracil prodrugs, 318
5-iodo-2′-deoxyuridine 5′-ester prodrugs, 887
5-methyl-10,11-dihydro-5H-dibenzo (a,d)-cyclohepten-5,10-imine, 474
5′-deoxy-5-fluorouridine, rectal administration, 318
5′-deoxy-5-fluorouridine, absorption from colon, 323
1,6-hexamethylene diamine, 714
99mTechnecium-sulfur colloid, 719
111In-labeled hydroxypropylmethylcellulose, 274

absorption enhancement, rectal, 91
absorption enhancement, sodium taurodihydrofusidate, 853
absorption enhancer, medium chain glycerides, 91
absorption of 5′-deoxy-5-fluorouridine, from colon, 323
absorption rate constant, apparent zero order, 133
ACE inhibitor, 759
acetaminophen, hepatotoxicity, 1025
acetylation procainamide metabolism, 477
acetylcholine esterase inhibitor, tacrine, 924
acetylcholine-brain levels, mice, 709
acetylcholinesterase, inhibition by H2 antagonist, 709
acid-base equilibria, piperazines, 177
activation energy, water transport, 564
acyclovir, blood brain barrier, 624
acyl migration, glucuronides, 125
adduct formation, teicoplanin, 1032
adinazolam, metabolism in elderly subjects, 379
adinazolam, pharmacokinetics, 379
adjuvant, muramyldipeptide activity, 748
adsorption, protein stability, 903
aerosol inhalation, 227
age, effect on skin barrier, 949
aggregation, protein stability, 903
aging, pharmacokinetics and pharmacodynamics, 379
agranulocytosis, reactive metabolites, 265
ajmaline, circular dichroism, 521
albumin, 107
albumin, cationized, glycosylated, 466
albumin, lactosylated, 110
alginate, sodium, 413
alkanes, distant matrix, 809
Alzheimer's disease, tacrine, 924
aminoglycosides, interaction with phospholipids, 362
aminopeptidase, buccal epithelium, 161
aminopeptidase, hamster cheek pouch, 966
aminopeptidase, inhibitors, -aminoboronic acids, 186
aminopeptidase, inhibitors, bestatin, 186
aminouracil derivatives, cardiovascular activity, 394
aminouracil diuretic, 394
aminouracil synthesis, 394
amoxicillin, otitis media, pharmacokinetics, 279
amphoteric gel, 44
analgesia, N-phosphinylamino-1,2,5,6-tetrahydropyridines, 737
analgesic activity, NSAID, 867
androgen, substitutional therapy, 641
angiotensin converting enzyme (ACE) inhibitor, moexipril, 971
angiotensin converting enzyme (ACE) inhibitors, 1043
angiotensin converting enzyme inhibitor, CGS 16617, bioavailability, 328
angiotensin converting enzyme, inhibitors, 759
anhydro-daptomycin, 387
anion-exchange copolymer, colestipol, 619
anthelmintic agents in rats, CDRI81-470, 991
antiarrhythmic activity, n-alkyl-1,2-diphenylethanolamines, 254
antiarrhythmic activity, verapamil, 254
antibiotics, in otitis media, 279
anticholinergic, scopolamine, 481
antiemetic, scopolamine, 481
antiepileptic, valpromide, 683
antihistamines, antiperspirant, 883
antimicrobial pharmacokinetics in otitis media, 279
antiperspirancy, H1 blockers, 883
antipyrine, blood brain barrier, 624
area function method, 133
Arrhenius behavior, swelling ratio constants, 564
asialoglycoproteins hepatic uptake, 106
asialoglycoproteins, RME, 194
aspirin, pharmacokinetics, 660
aspartyl peptides, stability, 903
aspartyl transpeptidation, daptomycin, 387
atenolol, cerebral distribution, 250
atenolol, nonlinear pharmacokinetics, 250
atherosclerotic rabbits, lipid disposition, 1011
atrial natriuretic polypeptide, RME, 194
atropine sulfate, antiperspirant, 883
autoradiography, tacrine, 924
azidothymidine, pharmacokinetics, rats, 734
azo-reduction, sulfasalazine, 1067
azone, effect, dose-dependent, on skin permeability, 798
azone, penetration enhancer, 286

Balaban's J index, 809
barbiturates, metabolism to N-glucosides, 458
basolateral membrane, transport, 954
benoxaprofen, glucuronides, stereochemistry, 125
benoxaprofen, toxicity, 265
benzodiazepine receptors, in hyperthyroidism, 404
benzodiazepines, endogenous origin, 1
benzodiazepines, natural products, 1
bestatin, aminopeptidase inhibitor, 186, 966
beta-blocker, atenolol, CSF levels, 250
beta-blockers, skin permeation, 628
betamethasone 17-valerate, HPLC, 431
betamethasone 21-valerate stability assay, 431
bile salt adsorption, colestipol, 619, 794
biliary excretion, 140
bioavailability by semisimultaneous drug administration, 817
bioavailability evaluation, 817
bioavailability in linear and nonlinear systems, 4
bioavailability trials, 328
bioavailability, 5′-deoxy-5-fluorouridine in rat, 323
bioavailability, cyclosporin, 40
bioavailability, etoposide, 408
bioavailability, furegrelate, 53

0724-8741/89/1200-1080$06.00/0 © 1989 Plenum Publishing Corporation

bioavailability, indomethacin, 44
bioavailability, insulin-collagen, 813
bioavailability, naproxen, 919
bioavailability, phenylpropanolamine, 274
bioavailability, scopolamine, 481
bioavailability, theophylline, dogs, 1039
biodegradable microspheres, 296
blood-brain barrier, in vitro model, 624
blood-brain barrier, NSAID, 667
blood-brain barrier, protein permeability, in vitro model, 466
body weight, estradiol, 592
boundary conditions, dissolution, 436
brain microvessel endothelial cells, 624
brain-enhanced chemical delivery system, 592
brittleness, sucrose, 373
brush border membrane, 308
brush-border membrane vesicles, rat intestinal, 302
buccal absorption, leucine-p-nitroanilide, 966
buccal epithelium, drug permeability, 160
buthionine sulfoxime, 1025

cadaver skin, 825
caffeine, blood brain barrier, 624
caffeine, skin penetration, 628
calcium ions, lipolysis, 449
calorimeters, 20
calorimetry, conduction, 20
calorimetry, heat, 20
carbamazepine dihydrate, x-ray diffraction, 1017
carbamazepine, dissolution, 612
carbamazepine, x-ray diffraction, 1017
carbidopa, coadministration with L-dopa, 501
carbonic anhydrase, solfonamides binding, 205
carboplatin, methotrexate interaction, 492
cardiac arrhythmia, calcium induced, rat, 254
cardiovascular reactivity, racial differences, 182
carrier-mediated intestinal absorption, ACE inhibitors, 1043
carrier-mediated transport, vincristine, 690
CDRI compound 81-470, HPLC, 991
cefazolin, 486
ceflacor, uptake by intestinal brush border membrane vescicle, 305
ceftibuten, characteristics of, 302
cellulose acetate butyrate-coated microcapsules, 517
cellulose acetate propionate, microspheres, 418
cellulose ethers, 313
centchroman, HPLC, 1048
centchroman, single-dose pharmacokinetics, 1048
cephalosporin, intestinal transport, 302
cephalosporin, membrane transport, 308
cephem, derivative, membrane transport, 308
cephradine, intestinal absorption, 1043
cerebrospinal fluid, atenolol levels, 250
CH COSY, NMR, 531
chemical drug delivery system through BBB, 667
chitosan, microencapsulation, 413
chloramphenicol-induced aplastic anemia, 269
chloroquine blood level, in mice, 787
chloroquine, liposome-encapsulated, 787
chlorpheniramine, antiperspirant, 883
chlorprothixene geometric isomers (cis/trans isomers), 706
cholesterol lowering effect of colestipol, 794
cholesterol, biosynthesis, 232
cholesteryl ester, nonhydrolyzable, 1011
cholinergic activity of H2-antagonist, 709
ciclosporin solubilization, 958
circular dichroism α_1-acid glycoprotein, 156
circular dichroism, reserpine, 521
cisplatin, lipiodol suspension, 342
cisplatin, localization in tumor, 342
citrate adsorption to colestipol, 796
clearance, intrinsic intestinal absorption clearance, 1056
clofibrate in atherosclerotic rabbits, 1011
clofibrate, dissolution, 612
clonidine, transdermal transport, 443
cluster analysis, neuroleptic receptor binding, 571
coated pits, 106
colchicine, hepatic uptake, 237
colchicine, microtubular, 237
colestipol anion adsorption competition, 794
colestipol hydrochloride, bile salt adsorption, 619, 794
colestipol in atherosclerotic rabbits, 1011
collagen, insulin co-injection, 813
collagenase-like peptidase, in subcutaneous tissue, 813
colloidal polymer dispersions, aqueous, 725
colon tumors in rats, 5'deoxy-5-fluorouridine, 318
colon, absorption of 5'-deoxy-5-fluorouridine, 323
colon-targeted delivery, naproxen, 919
compartmental models, 260
compartmental models, linear and nonlinear kinetics, 4
compressibility, polyvinylalcohol methyl acrylate copolymer, 844
concentration-effect relationship, barbiturates, 976
conjugation, diglucuronide, 28
connective index, 497
contraceptive drugs, transdermal delivery, 1000
controlled release of drugs, 241
controlled release, dapsone, 945
controlled release, phenylpropranolamine, 274
controlled release, propranolol, 753
controlled release, theophylline, 1039
controlled-release formulation, enalapril, 760
controlled-release formulation, moexipril, 760
copolymers, polyvinyl alcohol-methyl acrylate, 844
corneal membrane permeability, 887
cortisone acetate dissolution, 612
COSY, NMR spectra, 30, 531
covalent protein binding of drugs, 105
creatinine kinase, myotoxicity, 766
cunninghamella elegans, warfarin metabolism, 982
cyclic GMP, endothelium derived relaxing factors, 651
cyclic imides, hypolipidemic activity, 232
cyclodextrin-containing formulation, 641
cyclodextrin-testosterone, 641
cyclosporine, acute toxicity, 601
cyclosporine, formulation, 602
cyclosporine, intestinal absorption, 40
cyclosporine, liposomes, 601
cyclosporine, pharmacokinetics in rats, 254
cyclosporine, pharmacokinetics, dogs, 601
cyclosporine, solubilization, 958
cystic fibrosis, drug development, 525

d-tubocuranine, protein binding, 111
dapsone micropellets, 945
dapsone toxic reactions, 271
dapsone, dissolution profile, 945
daptomycin, stability, 387
deamination, protein degradation, 903
debrisoquin 4-hydroxylation, 13
decomposition kinetics, by calorimetry, 20
deformation kinetics, sucrose crystals, 1060
denaturation, protein stability, 903
dermal irritation test, contraceptive patches, 1000
desacetyldiltiazem, HPLC in plasma, 428
desmethyldiazepam, natural products, 1
dextran ester prodrugs, naproxen, 919, 995
dextran, fluid phase marker, 71
dextran, glutathione conjugate, 1025
dextranases, g.i. tract, 995
dextromethorphan, conjugation, 13
dextromethorphan, polymorphic metabolism, 13
dextrose, teicoplanin adducts, 1032
diazepam, binding to α_1-acid glycoprotein, 156
diazepam, gas chromatography/mass spectrometry, 2
diazepam, i.v. formulation, toxicity, 510
diazepam, myotoxicity upon i.m. injection, 167
diazepam, natural products, 1
diazepam, submicronized emulsion, 510

diazepam, venous sequelae after injection, 510
differential scanning calorimetry, 798
diffusion cell, 431
diffusion model, 931
diglucuronide, nalmefene, 28
dihydropyridine prodrugs, NSAID, 667
dilantin, myotoxicity upon i.m. injection, 167
diltiazem, HPLC in plasma, 428
dipeptide transport, 308
dipeptides, hydrolysis in intestinal tissue, 69
dipeptides, intestinal permeability, 66
diphenhydramine, antiperspirant, 883
diphenylhydramine, lung binding, 877
dissociation constants, narcotic analgesics, 147
dissolution kinetics, 438
dissolution of drugs from transdermal patches, 346
dissolution of ionizable drugs, 436
dissolution of water-insoluble drugs, 612
dissolution profile, water-insoluble drug dosage forms, 612
dissolution with sodium lauryl sulfate, 612
dissolution with surfactants, 612
dissolution, etoposide, 408
distance matrix, alkanes, 809
distribution volumes, cefazolin, tobramycin, 486
disulfide exchange, protein, 903
dodecyl,N.N-dimethylamino acetate, penetration enhancer, 443
dopamine agonist, fenoldopam, 702
dopamine, delivery by ion exchange, 96
dopamine, HPLC, 97
dose ranging, pharmacokinetics, zidovudine, 734
doxorubicin, hepatic first-pass effect, 833
drug delivery, ion exchange, 96
drug delivery, liposomes, 633
drug delivery, transdermal, 355
drug metabolism, epidermal, 33
drug release, poly(vinyl alcohol)micromatrices, 578
drug release, swellable micromatrices, 578
drug response, racial differences, 182
drug targeting to the liver, 105
drug targeting, kinetic model, 367
drug transport, transdermal, 33
drug-nutrient interactions, 332

EDTA, peptidase inhibitor, 91
eigenvalue of the distance matrix (DI), 809
elderly subjects, adinazolam, 379
electron microscopy, buccal epithelium, 161
electroosmosis, 85
elimination kinetics of drugs, first order and nonlinear, 260
emulsion diazepam, 510
emulsion dosage form, cyclosporine, 40
emulsion processing, 748
emulsion stability, 748
emulsion vehicle, adjuvant muramyldipeptide, 748
emulsion, droplet size, 40
emulsion, ethyloleate, 555
emulsion, phenytoin prodrugs, 555
emulsion, triglyceride, 555
emulsion, triglyceride/lecithin, 449
enalapril, controlled release, 759
enalapril, intestinal absorption, 1043
enalapril, site specific absorption, 759
enalaprilat, controlled release, 759
enalaprilat, site specific absorption, 759
endocytosis, adsorption, 466
endocytosis, fluid phase, 466
endocytosis, receptor mediated, 105, 194
endorphins, des-enkephalin-γ-endorphin, 91
endosome, 106
endothelial cell monolayers, bovine brain microvessel, 624
endothelial cells, bovine brain capillary, 466
endothelium-derived relaxing factor, 651
epidermal growth factor, endocytosis
epidermal growth factor, pharmacokinetic model, 194
epidermal growth factor, receptor down regulation, 194
epidermis and dermis separation, 740
epidermis, human, ultrasound, 697
epidermis, transport and metabolism, 119
epithelial cell monolayer, madin darby canine kidney cells, 71, 78
epithelium, buccal, primary culture, 160
equal absorption and elimination rate constants, 731
erosion control, oxprenolol release, 313
erythrocyte barrier, hepatic elimination, 833
erythrocytes, sulfonamide binding, 205
ester prodrugs, NSAID, 867
esterase inhibitors, 38
esterase, in epidermis, 119
estradiol, chemical delivery system, 592
estradiol, CNS effects in rats, 592
estrone, blood brain barrier, 624
ethanol, myotoxicity, 766
ethyl cellulose, micropellets, dapsone, 945
ethylene vinyl acetate copolymers, drug delivery, 938
etoposide, bioavailability, 408
etoposide, preformulation, 408
etoposide, solubility, 408
exocytosis, 106
extensor digitorum longus, myotoxicity in rat, 167

f-Met-Leu-Phe, chemotaxis, 78
fatty acids, biosynthesis, 232
fatty acids, protein binding, 111
fatty acids, skin penetration enhancers and irritants, 246
fatty acids, skin penetration, 628
fenoldopam, intrarenal formation from its metabolites, 702
fenoldopam, renal excretion, 702
fentanyl, solubility and dissociation constants, 147
fiber membrane, ion exchange drug delivery, 96
flufenamic acid, binding to α_1-acid glycoprotein, 156
fluid-phase endocytosis, 466
fluid-phase markers, 71
flunitrazepam, anticonvulsant effect, 585
flunitrazepam, kinetics-dynamics, 585
flunitrazepam, receptor binding-effect, rats, 585
fluorescein isothiocyanate dextran, 160
fluorescein, model drug in aerosol, 227
food effects, bioavailability in dogs, 1039
food intake, estradiol, 592
formulation design, in vitro/in vivo, contraceptive drugs, 1000
fosinopril, intestinal absorption, 1043
fourier transform-infrared/attenuated total reflectance (FT-IR/ATR), 608
fracture toughness, sucrose, 373
freeze drying, sucrose, 961
furegrelate, HPLC, 53
furegrelate, oral administration, 53
furegrelate, pharmacokinetics in humans, 53

gamma scintigraphy, 125I-cholesteryl iopanoate, 1011
gamma scintigraphy, GI transit, 719
ganciclovir, blood brain barrier, 624
gas chromatography/mass spectrometry, nitrosamines, 892
gastric emptying, dogs, 506
gastric irritancy, 44
gastric residence time, 719
gastric residence time, erodible device, 506
gastric retention device, 506
gastric ulcer, indomethacin, 44
gastrointestinal (GI) tract, pig, 995
gastrointestinal erosion, NSAID, 867
gastrointestinal transit by scintigraphy, 274
gel formulation, nitrosamine content, 892
gel, amphoteric, indomethacin, 44
gelatin beadlets, succinylsulfathiols, 517
gelatin matrices, swelling, 564
gelatin microspheres, interferon, 422
gelatin precoating of microspheres, 296
gender difference, barbiturate pharmacodynamics, 976

gentamycin, liposome interaction, 362
glassy gelatin, 564
glucose levels, blood, rats, 737
glucose monitoring, iontophoresis, 988
glucuronidation, enantioselective, 125
glucuronides, NMR, FAB-MS, 28
glutamate-induced neuronal damage, 474
glutaraldehyde, cross linking polyvinylalcohol, 578
glutathione dextran conjugate, 1025
glutathione, intrahepatic delivery, 1025
glutathione-S-transferase, 111
glycerides, medium chain, absorption enhancers, 91
glycerol, blood brain barrier, 624
glycoproteins as drug carriers, 105
glycosylated albumin, 466
graph theory, 809
griseofulvin, dissolution, 612
guanylate cyclase, nitric oxide- heme activation, 651

H1 blockers, anticholinergic activity, 883
hair follicle distribution, 85
haloperidol, blood brain barrier, 624
halothene-induced hepatic necrosis, 266
hamster pouch epithelium, 160
hardness, sucrose, 373
HDL cholesterol, 232
Heidelberg capsule, 719
hepatic acinus, 105
hepatic arterial injection of cisplatin, 342
hepatic blood flow rate, 874
hepatic blood supply, 105
hepatic carcinoma, VX-2, cisplatin delivery, 342
hepatic cell types, 105
hepatic clearance, 105
hepatic clearance, cyclosporine, 254
hepatic elimination, distributed models, 874
hepatic elimination, erythrocyte barrier, 833, 840
hepatic elimination, propranolol, 840
hepatic first pass effect, propranolol, 840
hepatic first-pass metabolism, erythrocyte barrier, 833
hepatic uptake, 140
hepatic uptake, colchicine, 237
hepatobiliary transport, 112, 140
hepatocyte, isolated, colchicine, 237
hepatocytes, 105
hepatotoxicity acetaminophen, 1025
hepatotoxicity, drug induced, 266
heptabarbital pharmacodynamics, 976
histamine-H2-antagonists, cholinergic activity, 709
HOHAHA, NMR, 531
hollow fiber, propranolol delivery, 1052
hollow fibers, polyurethane, 49
HPLC, 2′,3′-didehydro-3′-deoxythymidine, 895
HPLC, benoxaprofen glucuronides, 125
HPLC, betamethasone 17 valerate, 431
HPLC, CDRI-81-470, 991
HPLC, centchroman, 10458 oral sustained-release delivery propranolol, 1052
HPLC, diltiazem in plasma, 428
HPLC, dopamine, 97
HPLC, enantiospecific, metoprolol, 152
HPLC, furegrelate, 53
HPLC, indomethacin, 45
HPLC, insulin derivatives, 171
HPLC, ketorolac, 63
HPLC, oligoglycines, 100
HPLC, prostaglandin E1, 212
HPLC, stereospecific, benoxaprofen glucuronides, 125
human skin, phonophoresis, 697
hyaluronan metabolism, 677
hyaluronan pharmacokinetics in sheep, 677
hyaluronic acid (hyaluronan), 677
hydrocortisone, controlled release SDS from micelles, 241
hydrogel, polyvinyl alcohol, 338
hydrogel, sustained drug release for rectal administration, 338
hydrophilicity, mucosal permeability, 848
hydroxypropyl-β-cyclodextrin, 641
hydroxypropylmethylcellulose, 111In-labeled, 274
hydroxypropylmethylcellulose, 313
hyperlipidemic mice, 232
hypersensitivity reactions, 265
hyperthyroidism, oxazepam pharmacodynamics, 404
hypolipidemic activity, cyclic imides, semicarbazone, 232

ibuprofen, magnesium oxide interaction, 804
ibuprofen, phonophoresis, 697
idiosyncratic drug reactions, 265
ileocecal junction, 719
imipramine, binding to α1-acid glycoprotein, 156
imipramine, lung binding, 877
immunomodulator, tilorone, 477
immunopotentiator, muramyl dipeptides, 296
immunosuppressant, cyclosporine, 40
in vitro diffusion, 825
in vitro–in vivo correlation, 313
indigestible solid, GI transit, 719
indomethacin, amphoteric gel, 44
indomethacin, dihydropyridine prodrugs, 667
indomethacin, gastric ulcer, 44
indomethacin, HPLC, 45
indomethacin, ointment, 288
indomethacin, rectal administration, 338
indomethacin, transdermal penetration, 286
indomethacin, transdermal transport, 443
inflammation, neutrophil chemotaxis, 78
infrared spectroscopy, FT-IR/ATR, 608
inhalation, aerosols, 227
injectable emulsion, venous sequelae, 510
inositol phospholipids, synthesis, 218
insulin, immunoreactivity assay, 174
insulin, nasal administration, rats, dts, 853
insulin, palmitoyl derivative, 171
insulin, palmitoyl, hypoglycerin effect in rats, 171
insulin, RME, 194
insulin-collagen, co-injection, 813
interface, emulsion, PGE, stability, 212
interfacial peptides, 779
interfacial polycondensation, 714
interferon inducers, effect on N-acetylation, 477
interferon, microspheres, 422
intersubject variability, CGS 16617, bioavailability, 328
intestinal absorption, cyclosporine, 40
intestinal absorption, kinetics, 1056
intestinal brush-border membrane vesicles, 302
intestinal drug absorption, luminal perfusion, 1056
intestinal permeability, L-α-methyldopa derivatives, 66
intracellular routing and processing, 106
intragastric pH, 719
intrahepatic delivery, glutathione, 1025
intraindividual variability, bioavailability, 817
intramuscular injection, 167
intramuscular injections, myotoxicity, 766
intramuscular, injection, sex differences, 660
intrasubject variability, CGS 16617, bioavailability, 328
inulin, fluid phase marker, 71
ion exchange, across fiber membrane, 96
ion exchange, drug delivery through membranes, 96
ion pair transport (IPT), 743
ion pairing, effect on pharmacokinetics, 743
ion pairs, cationic drugs-fatty acids, 628
ion transfer, 85
ionization constants, microscopic, 177
ionization equilibrium, 438
ionotropic gelation, 413
iontophoresis, 85, 355
iontophoresis, noninvasive sampling biological fluids, 988
iontophoretic transport, nonionized model compounds, 85
isolated perfused rat liver, 874

isolated rat liver, 833, 840
isoniazid hepatotoxicity, 266
isopropyl myristate, skin penetration, 628
isoproterenol effects, racial differences, 528
isoproterenol, pharmacodynamics in American negroes and caucasians, 182

J index, alkanes, 809
jejunum permeability, monkey, rabbit, 857

keratin extraction, 161
ketorolac tromethamine, oral intramuscular administration, 62
ketorolac, dose proportionality, 62
ketorolac, HPLC, 63
ketorolac, pharmacokinetics in humans, 62
kmeria duperreana, aromatic constituents, 637
kmeriol, isolation, 637
Kupffer cells, 105

L-α-methyldopa, uptake kinetics, intestines, 66
L-α-methyldopa-L-phenylanaline, uptake kinetics, intestines, 66
L-dopa ester prodrugs, 501
L-dopa, prodrugs, 501
L-Glutamate, excitory neurotransmitter, 474
Laplace transform, fast inversion, 931
latexes, film casting, 725
lauric acid, drug ion pairing, 628
LDL cholesterol, 232
lecithin, emulsions, stabilized, 449
lens, timolol diffusion, 772
leucine-enkephalin, nasal absorption, 186
leucine-p-nitroanilide, 966
leukemia cells, P388, multidrug resistant, 690
leukocytes, idiosyncratic drug reaction, 265
levonorgestrel, transdermal delivery, 938
levonorgestrel/estradiol combination, transdermal delivery, 1000
ligandin, 111
lipase, prodrug hydrolysis, 555
lipase, triglycerides emulsions, 449
lipid emulsion, 212
lipiodol, cisplatin suspension, 342
lipopeptide antibiotic, 387
liposomal chloroquine, 787
liposome, aggregation, 362
liposome, cromoglycate, 633
liposome, cyclosporine, 601
liposome, fluid state and gel state, 787
liposomes, aminoglycosides, 362
liposomes, nitroimidazole partitioning, 399
liposomes, transport in neutrophils, 78
lithium pharmacokinetics in rats, 817
liver perfusion, EGF kinetics, 194
liver perfusion, rat, 140
Loo-Riegelman method, 133
lovastatin, decomposition, 20
lovastatin, oxidation, 20
lucifer yellow CH, fluid phase marker, 71, 78
lung drug accumulation, 877
lung mitochondria, basic drug binding, 877
lupus, drug induced, 265
lyophilized powder, moexipril stability, 971
lyophilized sucrose, 961
lysosomal degradation of the glycoprotein carrier, 115

macromolecular dextran ester prodrugs, 995
macromolecular network, polyvinylalcohol, 578
macromolecular prodrugs, naproxen, 919
macrophage, phagocytosis, interferon microspheres, 422
macrophages, phagocytosis, 296
madin darby canine kidney (MDCK), epithelial cell monolayer, 71, 78
magnoliaceae, aromatic constituent, 637
malignant cell lines, HL60, BG-1, BG-3, 218
mammary adenocarcinoma in CD8FI mice, 863
mean absorption time, 4
mean residence time, 4, 260
medroxyprogesterone, dissolution, 612
melting points, narcotic analgesics, 825
membrane peptides, 779
membrane proteins, interfacial amino acids, 779
membrane transport of ion pairs, 743
membrane transport, phenytoin, 332
metabolism, buccal epithelium, 160
metabolism, in skin, 119
metabolites sulfasalazine, 1067
methotrexate, carboplatin interaction, 492
metoclopramide, lung binding, 877
metoprolol, enantiospecific HPLC, 152
metoprolol, radioreceptor assay, 152
metronidazole, complex with sodium urate, 58
metronidazole, photodegradation, 58
mice, athymic, 33
micelle, SDS, 241
micelles, phenytoin prodrugs, 555
Michaelis-Menten elimination, 4, 260
Michaelis-Menten kinetics, hyaluronan, 677
microbial models of mammalian metabolism, 982
microcalorimetry, lovastatin, 20
microcapsules, cellulose acetate butyrate coated, 517
microcapsules, theophylline, 714
microencapsulation, 413
microfluidizer, 748
microindentation sucrose crystals, 1060
microindentation, fracture toughness, 373
micropellets, dapsone, 945
microporous membranes, controlled drug release, 241
microsperes theophylline, 418
microspheres, 413
microspheres, core size, 418
microtubule, colchicine, 237
microwave technique, skin sectioning, 740
moexipril lyophilization, 971
moexipril stability, 971
moexipril, ACE inhibitor, 759
molecular branching, 809
molecular connectivity, 497
molecular fragments, data base search, 497
molecular modeling, phenobarbital N-glucosides, 458
moment analysis, 4, 133
moment analysis, biliary transport, 140
mono-N-desmethyladinazolam, 379
monoamine oxidase (MAO) binding of basic drugs, 877
monocytes, idiosyncratic drug reaction, 265
monolayer, madin darby canine kidney (MDCK), 71
morphinan, conjugation, 28
morphine, solubility and dissociation constants, 147
motion sickness, scopolamine, 481
mucosal absorption, 848
multidrug resistance, P388 cells, 690
multilaminate adhesive device, propranolol delivery, 753
multiple dosing, 731
multiple indicator dilution method, 194
multiple internal reflectance infrared (MIR), ibuprofen-MGO interaction, 804
multiple-dose pharmacokinetics, adinazolam, 379
muramyl dipeptide, immuno potentiator, 296
muramyldipeptide adjuvant, 748
muramyldipeptide, 748
muscle damage, i.m. injection, in vitro model, 167
mutagenesis, protein stability, 903
myeloperoxidase, idiosyncratic drug reaction, 265
myotoxicity, 766
myotoxicity, binary solvent mixtures, 766
myotoxicity, intramuscular injections, 766
mytotoxicity, in rat, 167

N-(1-(2-thienyl)cyclohexyl)piperidine, dissociative anesthetic, 474
n-alkanoic acids, iontophoresis, 85

n-alkanols, iontophoresis, 85
N-alkyl-1,2-diphenylethanolamines, antiarrhythmic activity, 254
N-demethylation, dextromethorphan, 13
N-glucosides, phenobarbital, 458
N-methyl-D-aspartate (NMDA) receptor, 474
N-nitrosodiisopropanolamine, GC/MS, 892
N-phosphinylamino-1,2,5,6-tetrahydropyridines, analgesia, 737
N-phosphinylamino-1,2,5,6-tetrahydropyridines, blood glucose levels, 737
nalmefene, 3-O-glucuronide, 28
naloxone skin penetration, 246
nanoparticles, 413
naphazoline, skin penetration, 628
naproxen bioavailability in pigs, 919
naproxen dextran ester prodrugs, 995
naproxen dihydropyridine prodrugs, 667
naproxen regeneration, 995
naproxen, macromolecular prodrug, 919
narcotic analgesic, dissociation constants, 147
narcotic analgesics, permeability coefficients, 825
narcotic analgesics, pH solubility profiles, 147
narcotic analgesics, solubility, 147
narcotic antagonist, nalmefene, 28
nasal absorption, progesterone, 848
near-infrared spectroscopy, sucrose water content, 961
nephrotoxicity, aminoglycosides, 362
neuroleptics, rat brain receptor, 571
neuroleptics, receptor binding versus effect, 571
neuropeptides, rectal absorption, 91
neutrophil extravasation, 78
neutrophils, idiosyncratic drug reaction, 265
nitrate esters activation, 651
nitric oxide, endothelium derived, 651
nitroglycerin activation, 651
nitroimidazoles, partitioning in n-octanol/saline, 399
nitroimidazoles, QSAR pharmacokinetics, 399
nitrosamines, GC/MS, 892
NMDA receptor binding, 474
NMR, HMBC, COSY, INEPS, HETCOR spectra, 30
NOESY, NMR, 531
nomifensine, toxicity, 265
noncompartmental parameters, 731
noninvasive imaging, atherosclerosis, 1011
noninvasive sampling, iontophoresis, 988
nonlinear pharmacokinetics, atenolol, 250
nonlinear regression, 133
nonsteroidal antiinflammatory (NSAID) prodrugs, 867
nonsteroidal antiinflammatory drugs, 667
nonsteroidal antiinflammatory drugs, benoxaprofen, 125
nuclear magnetic resonance (NMR) cis/trans chlorprothixene, 706
nuclear magnetic resonance (NMR) spectroscopy, two dimensional, 531
nuclear Overhausen effect (NOE) chlorprothixene isomers, 706
nutrient drug interaction, 332
nylon microcapsules, 714

O-demethylation, dextromethorphan, 13
obese children, volume of distribution of antibiotics, 486
ocular aqueous humor, drug concentration, 887
ocular drug delivery, timolol in rabbits, 772
ocular kinetics of timolol, model, 772
ocular transport, 5-iodo-2′-deoxyuridine prodrugs, 887
oleic acid, drug ion pairing, 628
oligo glycines, models for peptide absorption, 100
oligoglycines, HPLC, reverse phase, 100
opioids, endogenous, 1
oral cephem, transport, 308
oral delivery system, phenylpropanolamine, 49, 844
oral drug delivery, microspheres, 413
organic nitrate esters, 651
otitis media, experimental animal models, 279
ovariectomized rats, estradiol administration, 592
oxazepam, natural products, 2
oxazepam, pharmacokinetics in hyperthyroidism, 404
oxidation, protein degradation, 903
oxprenolol release, 313
oxygen radicals in biology and medicine, 900

p-aminohippurate, transport, 954
p-hydroxyketorolac, metabolite of ketorolac, 62
palmitoyl derivative, insulin, 171
pancreatic lipase, 449
pancreatic lipase, prodrug hydrolysis, 555
Parkinson's disease, L-dopa prodrugs, 501
particle size analysis, 748
particle size, microspheres, 418
particle size, suspensions, 227
partition coefficient, etoposide, 408, 411
partition coefficients, narcotic analgesics, 825
partitioning of nitroimidazoles, 399
passive transport, jejunum, 857
penetration enhancer, azone, 798
penetration enhancers, by ion pairing, 628
penetration enhancers, transdermal, amino acetate, 286
peptidase inhibitor, EDTA, 91
peptide degradation pathway, 387
peptide, lipophilic derivatives, 171
peptides hormones, endocytosis, 194
percutaneous absorption, 931
percutaneous absorption, indomethacin, 286
percutaneous absorption, phonophoresis, 697
permeability coefficient, skin, 443
permeability, jejunum, 857
permeation enhancers, ethyl acetate, ethanol, 938
petrolatum ointments, indomethacin, 288
pH-profiles, daptomycin, 387
pH-solubility profiles, narcotic analgesics, 147
phagocytosis by neutrophils, 78
phagocytosis, macrophage, interferon microspheres, 422
phagocytosis, macrophages, 296
pharmacodynamic model, drug targeting, 367
pharmacodynamics, adinazolam, 379
pharmacodynamics, barbiturates, 976
pharmacodynamics, oxazepam, 404
pharmacokinetic parameters, nitroimidazoles, 399
pharmacokinetics in elderly, 379
pharmacokinetics, aspirin, 660
pharmacokinetics, carboplatin in cancer patients, 492
pharmacokinetics, cromoglycate, man, 633
pharmacokinetics, cyclosporine, 254, 601
pharmacokinetics, drug targeting, 367
pharmacokinetics, fenoldopam, 702
pharmacokinetics, hyaluronan, sheep, 677
pharmacokinetics, phenylpropanolamine, 844
pharmacokinetics, scopolamine, 481
pharmacokinetics, sulfasalazine, 1067
pharmacophores, 497
phenethylamines, activity, 254
phenindamine, antiperspirant, 883
phenobarbital N-glucosides, stability, 458
phenobarbital pharmacodynamics, 976
phenol red, liver uptake, 140
phenylbutazone-induced agranulocytosis, 270
phenylethylamine, lung binding, 877
phenylpropanolamine, bioavailability, 274
phenylpropanolamine, sustained release, 49
phenylpropanolamine, sustained release, pharmacokinetics, 844
phenytoin, 3-hydroxy, long chain fatty acid esters, 555
phenytoin, intestinal absorption, 332
phenytoin, lupus, 268
phenytoin, prodrug hydrolysis, 555
phonophoresis, transdermal, 355
phonophoretic drug delivery, 355
phophatidylinositol-4,5-diphosphate-containing liposomes, 362
phosphatidylcholine, cisplatin-lipiodol suspension, 342
phosphatidylinositol, ether linked derivatives, 218
phospholipid analogs, alkyl ether, 218

phosphoribosyl pyrophosphate, after uridine diphosphoglucose doses, 863
photodegradation, metronidazole, 58
piperazines, microscopic ionization constants, 177
plasmodium berghei infections, 787
platelet aggregation, nitric oxide effects, 651
platelet-activated factor, lipid analogs, 218
platinum, total, ultrafilterable in plasma, 492
poly(vinyl alcohol)micromatrices, cross-linked, 578
polycarbonate disks, collagen-coated, 163
polycarbonate membrane, 78
polycarbonate membranes, endothelial brain microvessel cell, 624
polyethylene glycol 400, myotoxicity, 766
polylactide microspheres containing muramyl dipeptide, 296
polymeric films, controlled drug release, 725
polymorphism, dextromethorphan metabolism, 13
polymorphonuclear neutrophil, 78
polysaccharide, chitosan, 413
polyurethane, segmented, fibers, 49
polyvinyl alcohol hydrogel, 338
polyvinyl alcohol-methyl acrylate copolymers, crystalline, 844
portacaval shunt, cyclosporine, 254
potentiometric titration, piperazines, 177
powder x-ray diffractometry, carbamazepine, 1017
practolol, toxicity, 265
precipitation, protein stability, 903
preformulation etoposide, 408
procainamide, acetylation, 477
procainamide, lung binding, 877
procainamide-induced lupus, 267
procainamide-tilorone, interaction, 477
prodrug hydrolysis, phenytoin, 555
prodrugs, ACE inhibitors, 1043
prodrugs, NSAID, 867
progesterone, blood brain barrier, 624
progesterone, controlled release SDS from micelles, 241
progesterone, hydroxylated, 848
propranolol HCl, in polymeric film, 725
propranolol, blood brain barrier, 624
propranolol, hepatic elimination, 840
propranolol, hollow fiber delivery system, 1052
propranolol, skin permeation, 753
propylene glycol, myotoxicity, 766
prostaglandin E1, dehydration, 212
prostaglandin E1, emulsion, stability in emulsion, 212
prostaglandin E1, HPLC, 212
protein binding of drugs, 105
protein binding of drugs, hydrophobic and electrostatic, 156
protein binding, effect on hepatic elimination, 874
protein kinase C inhibitors, 218
protein kinase C, HL60 cells, 218
protein pharmaceuticals, stability, 903
protein, chemical stability, 903
protein-lipid interactions, 779
proteinase inhibitors, 38
proteolysis, 903
proton-coupled uphill transport, 302
protonophore, FCCP, 302
proxyphylline, cross-linked poly(vinyl alcohol), 578
psychomotor performance, adinazolam, 379
pulmonary drug delivery, 633
pump incompatibility, cyclosporine, 601
pyridinium salts, prodrugs, 667
pyrilamine, antiperspirant, 883

quantitative structure-activity relationships (QSAR), nitroimidazoles, 399
quinine, lung binding, 877

racemization, protein degradation, 903
racial differences, isoproterenol effect, 528
radioreceptor assay, metoprolol, 152
radiosynthesis (±)1-iodo-MK-801, 474
radiotelemetry, GI transit, 719
raffinose monolaurate, 959
random effects, statistical model, 328
rat foot pad, sweat glands, 883
rauwolfia serpentina, reserpine assay, 521
reactive metabolites in leukocytes, 265
receptor binding, neuroleptics, 571
receptor internalization, EGF, 194
receptor mediated endocytosis, peptides, 194
receptor occupancy, flunitrazepam, 585
receptor-mediated endocytosis, 105
receptosome, 106
rectal absorption, 5′deoxy-5-fluorouridine, 323
rectal absorption, L-dopa esters, 501
rectal absorption, L-dopa prodrugs, 501
rectal absorption, peptides, in rats, 91
rectal absorption, progesterone, 848
rectal administration of indomethacin, 338
renal failure, transport function, 954
reserpine, circular dichroism, 521
reversible metabolism, fenoldopam, 702
ribavirin, blood brain barrier, 624
riboflavin effect on, 1067
ROESY, NMR, 531
rotating diffusion cell, ion pairs, 628

salicylate esters, skin absorption, 119
salicylic acid, diester derivative, 33
salicylic acid, HPLC, 46
salicylic acid, in polymeric film, 725
salicylic esters, skin metabolism, 33
scintigraphy, gastrointestinal transit, 274
scopolamine pharmacokinetics in normal subjects, 481
scopolamine, bioavailability, 481
SDS micelles, 241
sebacoyl chloride, 714
semicarbazone, 232
senile dementia, tacrine, 924
serine proteinase inhibition, 38
sex differences, asparin pharmacokinetics, 660
sex differences, intramuscular injection, 660
sialic acid, 106
site specific absorption, moexipril, 759
skin barrier function, effect of age, 949
skin drug metabolism, 119
skin graft, human, in athymic mice, 33
skin irritation, fatty acids, 246
skin layer separation, 740
skin model, two-layer, 931
skin penetration enhancers, fatty acids, 246
skin penetration model, 931
skin permeability, 355
skin permeability, azone, 798
skin permeability, narcotic analgesics, 825
skin permeation of cationic drugs, 628
skin permeation, propranolol, 753
skin pores, 355
skin retention, 740
skin sectioning, microwave, 740
skin transport, pH effect, 443
skin, drug transport, 119
skin, excised human, 628
skin, human cadaver, 825
skin, human facial drug transport, 119
skin, human, 33
skin, iontophoresis, 988
skin, metabolism, 33
skin, nude rats, iontophoresis, 85
skin, phonophoresis, 355
skin, transport of basic and acidic drugs, 443
sleeping time, barbiturates, 976
small bowel transit time, 719
snake skin, percutaneus absorption, 286
snakeskin transport, 443
sodium cromoglycate, pharmacokinetics, 633

sodium dodecylsulfate (SDS) micelles, 241
sodium salicylate, skin penetration, 628
sodium taurodihydrofusidate, absorption enhancer, 853
sodium urate, complex formation, 58
solid surfactant solution, ciclosporin, 958
solid-state interaction, ibuprofen-MGO, 804
solid/liquid boundary, 438
solubility indomethacin, 445
solubility, narcotic analgesics, 147, 825
solubilization, of drugs in micelles, 241
species correlation, jejunum permeability, 857
sprays, aerosol, 227
stability, contraceptive drugs, 1000
stability, calorimetry, 20
stability, moexipril, 971
stability, etoposide, 408
stability, oxprenolol preparations, 313
stability, PGE, 212
stability, protein pharmaceuticals, 903
stability, phenobarbital N-glucosides, 458
stability-indicating, HPLC, betamethasone 17-valerate, 431
statistical moment, 931
stereoselective metabolism of warfarin, 982
stereoselective transport, 302
stratum corneum occlusion, 949
stratum corneum, 85, 753, 798, 931
structure elucidation, by two dimensional NMR
structure-pharmacokinetic relationships, valpromide derivatives, 683
subcutaneous injection, insulin-collagen, 813
subcutaneous tissue, peptidases, 813
succinylsulfathiazole, sustained release microcapsules, 517
sucrose crystals, deformation, 1060
sucrose crystals, fracture toughness, 373
sucrose water content, 961
sucrose, fluid phase marker, 71
sucrose-monolaurate, 959
sufentanyl, solubility and dissociation constants, 147
sugar esters, solubilizers, 958
sulfamethoxazole, FT-IR/ATR analysis, 608
sulfamethoxazole, otitis media, pharmacokinetics, 279
sulfasalazine metabolites, 1067
sulfonamides, binding to carbonic anhydrase, 205
sulfonamides, toxic reactions, 270
sulfoxide metabolites, H2-antagonists, 709
surface area, colestipol-HCl, 619
surfactants, biodegradable, 958
surfactants, effect dissolution, 612
suspension, pressurized, nonaqueous for aerosols, 227
sustained release, phenylpropanolamine, 49, 844
sustained release, propranolol, 1052
swellable micromatrices, 578
swelling oxprenolol release, 313

tablets, controlled release of oxprenolol, 313
tacrine, tissue distribution, 924
targeted drug delivery, by neutrophils loaded with liposomes, 78
taurocholate, hepatic elimination, 874
taurodeoxycholate (TDC) micellar solutions, 449
teicoplanin dextrose adducts, 1032
teicoplanin, gleicopeptide antibiotic, 1032
temperature, phonophoresis, 697
tertiary basic drug, lipid solubility, 877
testosterone, administration by bolus, 641
testosterone, administration by episode-like pulses in rats, 641
testosterone, behavioral and physiological effects, 641
testosterone, blood brain barrier, 624
testosterone, buccal administration, 641
testosterone, controlled release SDS from micelles, 241
tetraethylammonium transport, 954
theophylline, bioavailability in dogs, 1039
theophylline, cross linked poly(vinyl alcohol), 578
theophylline, microcapsules, 714
theophylline, microspheres, 418
thermal analysis, ibuprofen-MGO interaction, 804
thermodynamics, lovastatin decomposition, 20
thermodynamics, phenobarbital N-glucosides, 458
thioester prodrugs, NSAID, 867
thrombosis, nitric oxide effects, 651
thromboxane synthetase inhibitor, furegrelate, 53
ticrynafen hepatotoxicity, 266
ticrynafen, toxicity, 265
tilorone, immunomodulator, 477
tilorone-procainamide interaction, 477
timolol, diffusion in lens, 772
tobramycin, distribution in obese children, 486
TOCSY, NMR, 531
topological index, 809
toxicity, cyclosporine, 601
toxicophores, 497
trace analysis, nitrosamines, 892
transcellular transport, albumin, 466
transcellular vesicular transport, 71
transdermal contraceptive devices, 1000
transdermal delivery, 355
transdermal delivery, contraceptive drugs, 1000
transdermal delivery, narcotic analgesics, 825
transdermal delivery, propranolol, 753
transdermal drug transport, 119
transdermal patches, clonidine, scopolamine, in vitro release profile, 346
transdermal penetration enhancers, 286, 443
transdermal penetration enhancers, ion pairing, 628
transdermal transport, 33
transdermal transport, azone, 798
transepidermal water loss, 949
transepithelial electrical resistance, 71
transferrin, RME, 194
transition-state analogue inhibitors, 186
transmembrane domains of membrane proteins, 779
transpeptidation, 903
transpeptidation, daptomycin, 387
transport, β-lactam, oligopeptide, 308
transport inhibitors, ouabain, sulhydryl reagents, 237
transport of ion pairs across membranes, 743
transport receptor, 194
transport, across blood brain barrier, 466
transport, buccal epithelium, 160
transport, cellular, 71
transport, ceftibuten, 302
transport, dipeptide, 308
transport, facilitated, iontophoresis, 85
transport, neutrophil-mediated, 78
transport, non-Fickian, 564
transport, p-aminohippurate, 954
transport, passive in jejunum, 857
transport, transcellular vesicular, 71
triglyceride content, VLDL, 232
triglyceride emulsions, hydrolysis, 449
trimethoprim, FT-IR/ATR analysis, 608
trimethoprim, otitis media, pharmacokinetics, 279
tripelennamine, antiperspirant, 883
tumor bearing mice, uridine diphosphoglucose administration, 863
two-dimensional (2D) NMR, 531

ultrasonic drug delivery, 355
ultrasound, phonophoresis, 697
uranyl nitrate, renal toxicity, 954
urate, sodium, complex formation with metronidazole, 58
urea, blood brain barrier, 624
uridine diphosphoglucose, administration tumor bearing mice, 863
uridine triphosphate, after uridine diphosphoglucose doses, 863
urinary excretion, platinum, 492
ursolic acid, NMR, 531

vaccine adjuvant, muramylpeptides, 748
vaginal absorption, progesterone, 848
valence connectivity index, 497

valnoctamide, pharmacokinetics, 683
valproic acid, pharmacokinetics, 683
valpromide derivatives, structure-pharmacokinetics relationships, 683
vasodilation, nitric oxide, 651
verapamil, antiarrhythmic activity, 254
verapamil, internal standard for diltiazem HPLC, 428
vesicles, reverse-phase evaporation lipid, 78
vincristine efflux from P388 cells, 690
volume of distribution, antibiotics in obese children, 486

Wagner-Nelson method, 133
warfarin microbial metabolism, 982
water determination, near IR, 961
water swelling, gelatin matrices, 564

x-ray diffraction, carbamazepine, 1017
xylocaine, myotoxicity upon i.m. injection, 167

zero-flux conditions at a dissolution surface, 436
zero-order release, oxprenolol, 313
zero-order release, succinylsulfathiols, 517
zidovudine, pharmacokinetics, rats, 734
zomepirac, toxicity, 265